CELLINK has completed directed share issues of SEK 946 million to finance the acquisition of SCIENION AG and create further room for a continued M&A agenda
The Board of Directors of CELLINK AB (publ) (“CELLINK” or the “Company”) has resolved on directed share issues which in total amounts to 5,912,477 new shares of series B (corresponding to approximately 13.8 percent of the total number of outstanding shares in the Company) shares at a subscription price of SEK 160 per share. 4,287,477 shares are issued based on the authorization granted by the extraordinary general meeting on July 16, 2020 and 1,625,000 shares are issued subject to the subsequent approval of an extraordinary general meeting on September 11, 2020 (the “Share Issues”), which